Clinical research on oxaliplatin or irinotecan plus capecitabine for colorectal liver metastasis treatment
10.3969/j.issn.1000-8179.20140225
- VernacularTitle:伊立替康或奥沙利铂联合卡培他滨治疗结直肠癌伴肝转移的临床研究
- Author:
Yujuan CAO
;
Delin WANG
;
Chengwei LIU
;
Fang DU
;
Longying HAO
;
Feng CAO
;
Weiwei LI
;
Cong ZHAO
- Publication Type:Journal Article
- Keywords:
colorectal cancer;
clinical effect;
irinotecan;
capecitabine;
oxaliplatin
- From:
Chinese Journal of Clinical Oncology
2014;(9):593-596
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aims to evaluate the clinical effect and adverse reactions of oxaliplatin or irinotecan plus capecitabine treatment for colorectal liver metastases. Methods:Data from 125 cases of colorectal liver metastasis patients were continuously enrolled and randomized into two groups, i.e., 63 in group one (treatment group) and the other 62 in group two (the control group). Capecitabine was administered at 1 000 mg/m2 doses, twice a day from d1 to d14, to all patients. Irinotecan was administered at 150 mg/m2 in d1 to group one, and oxaliplatin was administered at 130 mg/m2 in d1 to group two. The drug administration cycle lasted for 21 days in both regimens, with at least 6 administration cycles. The total course was for 6 months at most. The therapeutic efficacy, median progression-free survival time, median survival time, short-term clinical effect, and adverse drug reaction were monthly determined. Results:The overall response rates and disease control rates were 33.3%and 66.7%in group one, respectively, and 35.5%and 70.9%in group two, respectively, with no significant differences between the groups (P>0.05). The median survival time and median progression-free survival time were 14 months and 5 months in group one, respectively, and 12 months and 5 months in group two, with no significant differences between the two groups (P>0.05). The level-Ⅲand-Ⅳadverse drug reactions mainly include hematological toxicity, gastrointestinal reactions, and hand-foot syndrome. The diarrhea frequency is obviously higher in group one than in group two, and the difference between the two groups is sta-tistically significant (P<0.05). No significant differences were observed in the other adverse reactions between the groups (P>0.05). Conclusion:The Oxaliplatin or Irinotecan plus Capecitabine treatment is effective for colorectal liver metastases, which enhances survival rate and reduces patient suffering because of it has less side effects and good tolerance. The treatment must be further generalized and clinically applied.
